New Leaf Venture Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
4
- Investments
-
252
- Portfolio
-
22
- Exits
-
168
New Leaf Venture General Information
Description
Founded in 2005, New Leaf Venture Partners is a venture capital investment firm based in New York, New York. The firm is focused on healthcare technology-focused and seeks to invest in the biopharmaceutical, information convergence, medical device, biological research, life science tool, and infrastructure sectors.
Contact Information
Website
www.nlvpartners.com
Year Founded
2005
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
- 156 Fifth Avenue
- Suite 820
- New York, NY 10010
- United States
+1 (646) 000-0000
New Leaf Venture Investments (252)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Harpoon Therapeutics | 23-Oct-2023 | PIPE | 00000 | Drug Discovery | Generating Revenue/Not Profitable | 000000 0000 |
| Star Therapeutics | 05-Sep-2023 | 00000 00000 | 0000 | Biotechnology | Clinical Trials - Phase 1 | |
| Harpoon Therapeutics | 27-Mar-2023 | 0000 | 0000 | Drug Discovery | Generating Revenue/Not Profitable | 000000 0000 |
| Kalderos | 09-Sep-2022 | 00000 00000 | 000.00 | Business/Productivity Software | Generating Revenue | |
| Arine | 17-Aug-2022 | 00000 00000 | 0000 | Outcome Management (Healthcare) | Generating Revenue | |
| Cleerly | 25-Jul-2022 | 00000 00000 | 00000 | Decision/Risk Analysis | Generating Revenue | 00000 00000 |
| Cleerly | 11-Mar-2022 | 00000 00000 | 000.00 | Decision/Risk Analysis | Generating Revenue | |
| Electra Therapeutics | 16-Feb-2022 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 1 | 00000 00000 |
| Star Therapeutics | 16-Feb-2022 | Early Stage VC | 00000 | Biotechnology | Clinical Trials - Phase 1 | 0000000 0000 |
| Neurana Pharmaceuticals | 16-Nov-2021 | Later Stage VC | 0000 | Drug Discovery | Out of Business | 000000 0000 |
New Leaf Venture Exits (168)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| DICE Therapeutics | 09-Aug-2023 | Merger/Acquisition | 00.00 |
| Glympse Bio | 09-Aug-2023 | 000000000000000000 | |
| Braeburn | 01-Aug-2023 | 000000000 00000000 | |
| Bluesight | 17-Jul-2023 | 0000000000 | |
| Escape Bio | 01-Sep-2022 | 0000000000: 000000 | |
| Akili Interactive | 19-Aug-2022 | 0000000 000000 | |
| Sierra Oncology | 01-Jul-2022 | 000000000000000000 | 00.00 |
| ReViral | 06-Apr-2022 | 000000000000000000 | 00000 |
| Karus Therapeutics | 01-Oct-2021 | Secondary Transaction - Private | |
| DICE Therapeutics | 15-Sep-2021 | IPO | 00000 |
New Leaf Venture Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
New Leaf Venture Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
New Leaf Venture Team (46)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Craig Slutzkin | Chief Financial Officer & Chief Operating Officer | New York, NY | |||
| Ronald Hunt | Co-Founder & Managing Director | 00 | 0 | 0 | New York, NY |
| Vijay Lathi | Co-Founder & Managing Director | 00 | 0 | 0 | New York, NY |
| Sam Brasch | Managing Director | 00 | 0 | New York, NY | |
| Martin Mackay Ph.D | Senior Advisor | 0 | 0 | New York, NY |
New Leaf Venture Co-Investors (164)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| OrbiMed | 6 | 0 | 0 |
|
|
| Novo Holdings | 0 | 0 | 0 |
|
|
| RA Capital Management | 0 | 0 | 0 |
|
|
| Cormorant Asset Management | 0 | 0 |
|
|
|
| Logos Capital | 0 | 0 | 0 |
|
|